There has been a longstanding belief in the medical fraternity that men undergoing prostate cancer treatment in Des Moines should not use testosterone supplements or shouldn’t undergo any kind of testosterone hormone replacement therapy as that can worsen the situation.

For more than half a century, until the early 2000s, it was typical of urologists to suggest that testosterone can cause prostate cancer and can also rapidly increase the likelihood of developing prostate cancer and hindering prostate cancer treatment in Des Moines. Men having prostate cancer were recommended against testosterone as it supposedly worsened the condition and hindered the treatments from working.

Over the last 20 years, there have been numerous researches and studies including medically proven cases wherein it is undisputedly inferred that testosterone has absolutely no correlation with prostate cancer, provided all treatments are monitored stringently.

Two prominent peer reviewed literatures JAMA and the NEJM have established that the assertion that high testosterone levels induce prostate cancer or lead to a poorer prostate cancer prognosis is unsupported. Interestingly, the studies and researches suggest that the contrary or the exact opposite may actually be true.

Studies show that low pretreatment testosterone levels in patients with prostate cancer or undergoing prostate cancer treatment in Des Moines are related to poor prognosis and a higher tumor burden.

Many studies have shown that it is acceptable to use exogenous testosterone in hypogonadal men following radical prostatectomy or brachytherapy.

One study conducted recently has inferred that men who have had a radical prostatectomy and have an undetectable PSA level can be safely treated with exogenous testosterone. However, the testosterone levels should be monitored by the urologist on a regular basis.


It is recommended that a follow-up PSA level is carried out every month while prostate cancer treatment in Des Moines is underway and after that, for at least three months and thereon the PSA level should be checked every other month. This is necessary according to a proven study of 2009 in which the authors inferred that testosterone therapy is effective in increasing testosterone levels to the eugonadal range without increasing PSA values or instigating a biochemical PSA recurrence in hypgonadal men who underwent a radical prostatectomy.

A published meta-analysis of 19 controlled studies have concluded that there is no increased risk of prostate cancer among men with serum testosterone levels in the therapeutic range and that there is no statistical increase in prostate cancer among men who have undergone testosterone therapy in comparison with men who opted for a placebo.